ArticleScientific reports2025
Pyrazolopyridine pyrimidone hybrids as potential DprE1 inhibitors, design, synthesis and biological evaluation as antitubercular agents.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Discovery of potent DprE1-targeted antitubercular agents: synthesis and evaluation of PBTZ169/TBA7371-based derivatives.Molecular diversity · 2026Article
- Advances in 1,3,4-thiadiazole-based cholinesterase inhibitors: toward novel therapeutics for Alzheimer's disease.Molecular diversity · 2026Review
- Synthesis, characterization, and DFT study of a novel pyrido[2',3':4,5]pyrimido[2,1-b][1,3]thiazines via Michael addition and intramolecular cyclization.BMC chemistry · 2026Article
- Exploring imidazo[1,2-a]pyridine hybrids in cancer therapy: ADMET profiling, molecular docking, MD simulations and DFT calculations.Scientific reports · 2026Article
- Design, synthesis and antitubercular evaluation of novel 5,6-diphenyl-1,2,4-triazine-piperazine derivatives targeting mycobacterial dihydrofolate reductase.ADMET & DMPK · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) remains a major global health challenge. This study presents the design, synthesis, and evaluation of some novel pyrazolo[3,4-b]pyridine-pyrimidone derivatives targeting Mycobacterium tuberculosis (Mtb). The compounds were assessed for anti-tubercular activity using the Microplate Alamar Blue Assay (MABA) against the Mtb H37Rv strain. Key derivatives (8 and 14) showed significant activity with minimum inhibitory concentration (MIC) values of 3.12 µg/mL, 12.5 µg/mL, respectively, comparable to the standard drugs and are nontoxic at their effective concentration as anti-TB agents. Molecular docking studies demonstrated strong binding interactions with DprE1 and Mtb-DHFR enzymes, suggesting inhibition of these critical proteins. Further computational analyses, including density functional theory (DFT) and molecular dynamics simulations, confirmed the binding stability of the compounds to the target proteins. Overall, these pyrazolo[3,4-b]pyridine-pyrimidone derivatives are potential leads for further development as future therapeutics for treating drug-resistant TB.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.